The global canine cancer screening market is poised for significant growth over the next decade, reflecting a surge in demand for innovative and early detection solutions for canine health. According to recent market projections, the market is estimated to be worth USD 1,397.0 million in 2024 and is expected to reach an impressive USD 2,087.9 million by 2034, driven by a compound annual growth rate (CAGR) of 4.1% between 2024 and 2034.
In 2023, the market generated USD 1,342.0 million in revenue, underscoring a consistent upward trend. This growth is attributed to increasing pet ownership, heightened awareness of canine cancer, and advancements in diagnostic technologies that enable early and accurate detection.
Key Market Drivers:
- Rising Awareness of Canine Health: Pet owners are becoming increasingly proactive about preventative care, leading to greater adoption of cancer screening solutions.
- Advancements in Veterinary Diagnostics: Innovations such as liquid biopsy and non-invasive screening methods are enhancing detection capabilities and fueling market growth.
- Expanding Pet Insurance Coverage: Comprehensive insurance plans for pets now often include cancer diagnostics, making screening more accessible.
Opportunities Ahead:
The growing emphasis on early detection and treatment offers significant opportunities for companies to develop advanced diagnostic tools tailored to diverse breeds and age groups. Additionally, collaborations between veterinary clinics, diagnostic labs, and pharmaceutical companies are expected to drive innovation and improve market penetration.
As the global pet care industry continues to evolve, the canine cancer screening market is set to play a pivotal role in safeguarding the health and longevity of dogs. Companies operating in this space are well-positioned to capitalize on the growing demand, further bolstered by supportive regulatory frameworks and technological advancements.
Key Takeaways from the Market Study
- By test, the liquid biopsy (blood-based tests) holds a lucrative market share value of 7%. Liquid biopsy, especially blood-based tests, has gained the highest share by test type in the canine cancer screening market owing to a number of advantages over other conventional methods of diagnosis. These diagnostic tests are non-invasive, hence requiring only a blood sample, thereby decreasing stress and discomfort for the animal.
- By technology, the next generation sequencing holds a 4% market value share in 2024. Therefore, NGS has emerged as the dominant technology in the canine cancer therapeutics market, which has fundamentally altered the way in which cancer is diagnosed and treated in dogs. NGS gives full genomic detail, allowing the identification of the exact genetic mutation or changes that may underlie cancer in dogs.
- K. emerges as the primary region, with an expected CAGR of 4.4% from 2024 to 2034, The highly developed veterinary healthcare infrastructure in the country, with a subsequent network of state-of-the-art veterinary clinics and diagnostic laboratories, is notably responsible for this. The facilities are fully equipped with state-of-the-art technologies such as next-generation sequencing and liquid biopsy critical to the next generation, early detection, and diagnosis of cancer cases in canines. “The growing awareness among pet owners about the importance of regular health check-ups and early cancer detection is also propelling market growth.” says an analyst of Future Market Insights.
Growing Market Interest: Explore Comprehensive Insights and Trends with Our Detailed Report!
Market Competition:
Many companies strategize to capture competitors or other companies that generate less revenue. Market players are spending high amounts on research and development for new products to expand their market share. For instance,
- In December 2023, Salarius Pharmaceuticals, Inca clinical-stage biopharmaceutical company and VolitionRx Limited a multinational epigenetics company, announced the signing of a research and development collaboration to advance rapid epigenetic profiling using Volition’s Nu.Q® technology.
- In June 2022, PetDx® an liquid Biopsy company for Pets™ and Antech® Diagnostics jointly announced that they have collaborated to make OncoK9®, the pioneering multi-cancer early detection (MCED) test for dogs, available to all Antech customers across North America.
Key Players of Canine Cancer Screening Market:
- IDEXX
- Mars Pedtcare
- Zoetis
- PetDx
- Molecular Diagnostics (MDxHealth)
- Biomérieux SA
- OncoK9
- Antech Diagnostics
- VolitionRx Limited
- Oncotect
- Heska Corporation
Key Segments of Canine Cancer Screening Market
By Test Type:
In terms of test type, the industry is segregated into liquid biopsy (blood-based tests), tissue biopsy, genomic testing and biomarker tests.
By Technology:
In terms of technology, the industry is segregated into next-generation sequencing (NGS), polymerase chain reaction (PCR), immunohistochemistry (IHC), flow cytometry and in situ hybridization.
By Cancer:
In terms of cancer, the industry is segregated into lymphoma, mast cell tumors, osteosarcoma and hemangiosarcoma.
By End User:
In terms of end user, the industry is segregated into veterinary clinics, veterinary hospitals, diagnostic laboratories, academic & research institutes, pet owners (home-based testing kits).
By Region:
Key countries of North America, Latin America, Western Europe, Eastern, South Asia, East Asia and Middle East and Africa (MEA) have been covered in the report.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube